

# **ESTIMATION OF CD4<sup>+</sup>, CD25<sup>+</sup> FOXP3<sup>+</sup> CELLS IN CHILDREN WITH TYPE 1 DIABETES**

Thesis

*Submitted for Partial Fulfillment of Master Degree  
in Pediatrics*

Submitted By

**Mohamed Samir Mohamed Ragheb**  
*M.B.,B.Ch.*

Under Supervision of

**Prof. Dr. Mona Abdel Kader Salem**  
*Professor of Pediatrics  
Faculty of Medicine -Ain Shams University*

**Prof. Dr. Mohamed Aboelasar Mohamed**  
*Professor of Pediatrics  
Faculty of Medicine -Ain Shams University*

**Dr. Dalia Mohamed Ibrahim**  
*Lecturer of Pediatrics  
Faculty of Medicine -Ain Shams University*

**Faculty of Medicine  
Ain Shams University**

**2012**

## List of Contents

Title	Page No.
<b>List of Tables .....</b>	<b>i</b>
<b>List of Figures .....</b>	<b>iv</b>
<b>List of Abbreviations .....</b>	<b>vi</b>
<b>Introduction .....</b>	<b>1</b>
<b>Aim of the work.....</b>	<b>4</b>
<b><u>Review of Literature</u></b>	
• Diabetes Mellitus .....	5
○ T1DM .....	9
○ Prevention of T1D .....	35
○ Management of Type 1 Diabetes.....	38
• Regulatory CD4 <sup>+</sup> CD25 <sup>+</sup> FOXP3 <sup>+</sup> T cells.....	45
○ Definition and characterization .....	45
○ Function of regulatory T cells .....	49
○ Identification of treg cells.....	57
○ Naturally occurring regulatory T cells .....	58
○ Induced regulatory T cells .....	61
<b>Subjects and Methods .....</b>	<b>66</b>
<b>Results.....</b>	<b>74</b>
<b>Discussion .....</b>	<b>95</b>
<b>Summary .....</b>	<b>107</b>
<b>Conclusion .....</b>	<b>110</b>
<b>Recommendations.....</b>	<b>111</b>
<b>References .....</b>	<b>112</b>
<b>Arabic Summary.....</b>	<b>---</b>

## List of Tables

Table No.	Title	Page No.
<b>Table (1):</b>	Etiological classification of diabetes mellitus.....	6
<b>Table (2):</b>	Characteristic features of type 1 compared with type 2 diabetes in young people .....	8
<b>Table (3):</b>	Criteria for the diagnosis of diabetes mellitus. ....	33
<b>Table (4):</b>	Types of insulin preparations and suggested action profiles according to the manufacturers .....	42
<b>Table (5):</b>	Plasma blood glucose and A1C goals for type 1 diabetes by age-group .....	45
<b>Table (6):</b>	Comparison between patients and controls as regards the age and sex.....	75
<b>Table (7):</b>	Demographic and clinical data of the patients group.....	76
<b>Table (8):</b>	comparison between patients and controls as regards hematological variables. ....	77
<b>Table (9):</b>	Description of the type of treatment of diabetes received by the patients. ....	79
<b>Table (10):</b>	Chronic microvascular complications of the studied patients.....	80
<b>Table (11):</b>	Description of the anthropometric data of the studied cases. ....	81
<b>Table (12):</b>	Comparison between the studied groups as regards their anthropometric measurements. ....	82
<b>Table (13):</b>	Comparison between patients and controls as regards different CD percentages.....	84
<b>Table (14):</b>	Comparison between complicated and non complicated cases as regards their CD parameters.....	86
<b>Table (15):</b>	Description of the percentage of the patients at different mean HbA1c% values.....	87
<b>Table (16):</b>	Relation between glycemic control and percentage of CD4+cells among patients.....	87
<b>Table (17):</b>	Relation between glycemic control and percentage of CD4+CD25+T regulatory cells among patients. ....	88
<b>Table (18):</b>	Relation between glycemic control and percentage of CD4+CD25 <sup>+high</sup> among patients. ....	88

## List of Tables (Cont.)

Table No.	Title	Page No.
<b>Table (19):</b>	Correlation between different studied CD parameters and the mean HbA1c% among patients.....	89
<b>Table (20):</b>	Correlation between the percentage of CD4+CD25+Tregs and the studied clinical and laboratory parameters in the patients group. ....	91
<b>Table (21):</b>	Correlation between the percentage of CD4+CD25 <sup>high</sup> T regulatory cells and some studied clinical parameters in the patients group.....	94
<b>Table (22):</b>	Correlation between the percentage of CD4+% and the studied clinical parameters in the patients group.....	95

## List of Figures

Page No.	Title	Figure No.
	<b>Figure (1):</b> The global prevalence estimates of diabetes in 2007 .....	10
	<b>Figure (2):</b> The global prevalence estimates of diabetes in 2025 .....	11
	<b>Figure (3):</b> Pathogenesis of type 1 diabetes .....	12
	<b>Figure (4):</b> Schematic representation of the autoimmune response against pancreatic $\beta$ cells .....	25
	<b>Figure (5):</b> Beta-cell mass at various stages in the natural history of diabetes .....	29
	<b>Figure (6):</b> Natural history of type 1 diabetes mellitus.....	32
	<b>Figure (7):</b> T1DM stages and interventions.....	36
	<b>Figure (8):</b> Treatment of diabetes module ISPAD consensus guidelines, 2007.....	40
	<b>Figure (9):</b> Proposed functions of regulatory T cells.....	50
	<b>Figure (10):</b> T regulatory (Treg) cells in the control of an allergic reaction .....	57
	<b>Figure(11):</b> T regulatory (Treg) cells in allergen-specific immunotherapy.....	58
	<b>Figure (12):</b> Flowcytometric picture represents gating of lymphocytes.....	72
	<b>Figure (13):</b> Flowcytometric picture represents gating of CD3+ lymphocytes.....	72
	<b>Figure (14).</b> An example of flow cytometry result showing the method for the assessment of CD4+CD25 <sup>high</sup> .....	73
	<b>Figure(15):</b> Distribution of family history of diabetes among patients.....	78
	<b>Figure (16):</b> Distribution of different types of insulin treatment received by the patients. ....	79
	<b>Figure (17):</b> The comparison between patients and controls as regards their means of height, weight and body mass index .....	83
	<b>Figure (18):</b> Flow cytometry report of patient number (11). The % of CD4+CD25+ is (45). And the % of CD4+CD25 <sup>high</sup> is (35.6).....	85
	<b>Figure (19):</b> Flow cytometry report of one of the control subjects. The % of CD4+CD25+ is (57.5). And the % of CD4+CD25 <sup>high</sup> is (3.7).....	85

## List of Figures (Cont..)

Page No.	Title	Figure No.
	<b>Figure (20):</b> Comparison between complicated and non complicated cases as regards their CD parameters. ....	86
	<b>Figure (21):</b> Scatter diagram showing correlation between mean percentage of CD4+CD25 <sup>high</sup> and haemoglobin A1C in diabetics. ....	89
	<b>Figure (22):</b> Scatter diagram showing correlation between mean percentage of CD4+CD25 <sup>+</sup> and haemoglobin A1C in diabetics. ....	90
	<b>Figure (23):</b> Scatter diagram showing the correlation between the mean percentage of CD4 +CD25 <sup>+</sup> and BMI in patients group. ....	92
	<b>Figure (24):</b> Scatter diagram showing the correlation between the mean percentage of CD4 +CD25 <sup>+</sup> and insulin dose (unit/KG/day) in diabetics. ....	92
	<b>Figure (25):</b> Scatter diagram showing the correlation between the mean percentage of CD4 +CD25 <sup>+</sup> and the duration of the disease in diabetics. ....	93
	<b>Figure (26):</b> Scatter diagram showing the correlation between the mean percentage of CD4 +CD25 <sup>+</sup> and age of patients. ....	93
	<b>Figure (27):</b> Scatter diagram showing significant correlation between the mean percentage of CD4+CD25 <sup>high</sup> and age in diabetics. ....	94

## List of Abbreviations

ADA.....	American Diabetes Association
APCs.....	Antigen Presenting Cells
BMI.....	Body Mass Index
BSA.....	bovine serum albumin
CD.....	Cluster of Differentiation
CTLA-4.....	Cytotoxic T lymphocyte associated factor-4
DC.....	Dendritic Cell
DCCT.....	Diabetes Control and Complications Trial
DKA.....	Diabetic Ketoacidosis
DM.....	Diabetes Mellitus
DNA.....	Deoxyribonucleic acid
DPT-1 .....	Diabetes Prevention Trial-1
EAE.....	Experimental autoimmune encephalomyelitis
ENDIT .....	The European Nicotinamide Diabetes Intervention Trial
Foxp3 .....	Forkhead box protein 3
FPG.....	Fasting plasma glucose
GAD65.....	Glutamic Acid Decarboxylase isoform 65
GALT.....	Gutassociated lymphoid tissue
GDM.....	Gestational diabetes mellitus
GITR.....	Glucocorticoid-induced TNF receptor
GRAIL .....	Gene related to anergy in lymphocytes
Hb .....	Hemoglobin
HbA1c.....	Glycosylated Hemoglobin
HDL .....	High density lipoprotein
HLA .....	Human Leucocytic Antigen
IA2.....	Insulinoma Associated Antigen -2
IAA .....	Insulin Auto-Antibody
IBD .....	Inflammatory bowel disease
ICA .....	Islet Cell Antibody
IDDM.....	Insulin Dependant Diabetes Mellitus
IFG.....	Impaired fasting glucose
IFN.....	Interferon
IGT.....	Impaired Glucose Tolerance
IL.....	Interleukin
IPEX .....	Immune dysregulation, polyendocrinopathy, Enteropathy X-linked syndrome
ISPAD.....	International Society for Pediatric and Adolescent Diabete
IVGTT .....	Intra Venous Glucose Tolerance Test
Jak.....	Janus kinase

**List of Abbreviations (Cont...)**

Kip1 .....	Cyclin-dependent kinase inhibitor p27
LDL.....	Low density lipoprotein
MAP.....	Mitogen-activated protein
MHC .....	Major Histocompatibility Complex
MODY .....	Maturity-Onset Diabetes of the Young
MRBG.....	Mean random blood glucose
MS.....	Multiple Sclerosis
NK.....	Natural killer
NKC.....	Natural Killer Cells
NKT .....	Natural killer T cells
NOD.....	Non-Obese Diabetic
OGTT.....	Oral Glucose Tolerance Test
PI3K.....	Phosphatidylinositol 3-kinase
PTPN22.....	Phosphatase non-receptor type 22
RA.....	Rheumatoid arthritis
RBCs.....	Red Blood Corpuscles
RNA.....	Ribonucleic acid
SD .....	Standard Deviation
SLE .....	Systemic Lupus Erythematosus
SMBG.....	Self Monitoring Blood Glucose
T1D .....	Type 1 Diabetes
TCR.....	T cell Receptor
TGF.....	Transforming growth factor
Th1&Th2 .....	T helper 1&T helper 2
TLC.....	Total Leukocytic Count
TNF.....	Tumor Necrosis Factor
Treg.....	T regulatory cell
VNTR .....	variable numbers of tandem repeat
WHO.....	World Health Organization
Wt .....	Weight



## INTRODUCTION

**D**iabetes mellitus (DM) is a chronic metabolic disorder caused by an absolute or relative deficiency of insulin, an anabolic hormone. Insulin is produced by the beta cells of the islets of Langerhans located in the pancreas, and the absence, destruction, or other loss of these cells results in type1 diabetes (*Lamb, 2011*).

Most diabetic cases fall under the Type 2 category, characterized by relatively late onset, development of insulin resistance and/or deficiency, and amyloidosis. Type 1 diabetes, on the other hand, manifests early during childhood and has an autoimmune component to it that causes a severe deficiency in the circulating levels of insulin. Despite the heterogeneity in etiology and clinical presentation, hyperglycemia is the most common metabolic abnormality in diabetic patients (*Lee and Pervaiz, 2007*).

Type 1 diabetes (T1D) is an autoimmune disease resulting from the destruction of insulin-producing pancreatic  $\beta$  cells by autoreactive T cells. Self-reactive CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes infiltrate the pancreas (insulitis) and selectively destroy the insulin producing beta-cells in the islets. This destruction occurs ‘silently and progressively’ and may stay undetected for many years (*Chentoufi et al., 2008*). Susceptible genes and environmental factors are important in the disease process, but the pathological mechanisms are still unknown

---

(*Knip et al., 2005*). Failure of immunoregulatory cells in maintaining peripheral tolerance to  $\beta$  cells is one plausible hypothesis (*Piccirillo & Thornton, 2004*).

T-cell tolerance is established centrally in the thymus and further strengthened and maintained through multiple mechanisms of peripheral tolerance (*Walker and Abbas, 2002*). An interest has focused on a feature of tolerance that seems to bridge the central and peripheral processes, namely the  $CD4^+CD25^+$  regulatory T-cell (*Sakaguchi, 2000*). T regulatory cells modulate a response to autoantigens and probably play a role in pathogenesis of type 1 diabetes (*Bluestone et al., 2008*).

Naturally occurring regulatory T cells arise during the normal process of maturation in the thymus (*Dejaco et al., 2006*).  $CD4^+CD25^+$  cells can be detected in peripheral blood in humans and are able to suppress proliferation and cytokine production from both CD4 and CD8 T-cells in vitro in a cell contact-dependent manner (*Piccirillo and Shevach, 2001*).

Although, islet infiltrates have shown the presence of cytotoxic effector T-cells and pro-inflammatory cytokines (*Donath et al., 2003*). There is still a major void in our understanding of how these effector cells escape peripheral regulation (*Jailwala et al., 2009*).

There is accumulating evidence of a deficiency in either the frequency or function of regulatory T-cells in various human autoimmune diseases (*Bacchetta et al., 2007*).

Results concerning the role of T regulatory cells in the pathogenesis of diabetes are diverse. Further more both the experimental and clinical studies are required including the use of those cells in immunotherapy. Most authors observed the lack of number and/or function of T regulatory cells in type 1 diabetes (*Luczyński et al., 2009*).

## **AIM OF THE STUDY**

**T**o evaluate the contribution of T regulatory cells in the pathogenesis of type 1 diabetes, through determination of the count and percentage of  $CD4^+CD25^+$  in the blood.

### **Hypothesis**

It is hypothesized that a relative defect of the number of regulatory T-cells ( $CD4^+CD25^+$ ) is estimated in type 1 diabetes.

## DIABETES MELLITUS

### **Definition:**

**D**iabetes Mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia, resulting from defects in insulin secretion, insulin action or both. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction and failure of various organs, especially the eyes, kidneys, nerves, heart and blood vessels (*American Diabetes Association, 2010*). It is the most common endocrine – metabolic disorder of childhood and adolescence (*Sperling, 2000*).

Diabetes mellitus has metabolic, vascular and neuropathic components that are interrelated; this makes DM a major health problem with long-term microvascular and macrovascular complications. The development and progression of diabetic complications are strongly related to the degree of glycemic control (*Özmen and Boyuada, 2003*).

### **Classification:**

WHO classified D.M. into clinical (normoglycemia, IGT/IFG, diabetes), and etiological types (*Pickup and Williams, 2003*).

**Table (1):** Etiological classification of diabetes mellitus.

<b>I.</b>	<b>Type 1 diabetes</b> ( $\beta$ -cell destruction, usually leading to absolute insulin deficiency) <ul style="list-style-type: none"><li>A. Immune mediated</li><li>B. Idiopathic</li></ul>
<b>II.</b>	<b>Type 2 diabetes</b> (may range from predominantly insulin resistance with relative insulin deficiency to a predominantly secretory defect with insulin resistance)
<b>III.</b>	<b>Other specific types</b> <ul style="list-style-type: none"><li>A. Genetic defects of <math>\beta</math>-cell function:<ul style="list-style-type: none"><li>1. Chromosome 12, HNF-1<math>\alpha</math> (MODY3)</li><li>2. Chromosome 7, glucokinase (MODY2)</li><li>3. Chromosome 20, HNF-4<math>\alpha</math> (MODY1)</li><li>4. Chromosome 13, insulin promoter factor-1 (IPF-1; MODY4)</li><li>5. Chromosome 17, HNF-1<math>\beta</math> (MODY5)</li><li>6. Chromosome 2, Neuro D1 (MODY6)</li><li>7. Mitochondrial DNA</li><li>8. Others</li></ul></li><li>B. <i>Genetic defects in insulin action:</i><ul style="list-style-type: none"><li>1. Type A insulin resistance</li><li>2. Leprechaunism</li><li>3. Rabson-Mendenhall syndrome</li><li>4. Lipoatrophic diabetes</li></ul></li></ul> <p style="text-align: center;"><b><u>Continued</u></b></p> <ul style="list-style-type: none"><li>C. <i>Diseases of the exocrine pancreas:</i><ul style="list-style-type: none"><li>1. Pancreatitis</li><li>2. Trauma/pancreatectomy</li><li>3. Neoplasia</li><li>4. Cystic fibrosis</li><li>5. Hemochromatosis</li><li>6. Fibrocalculous pancreatopathy</li><li>7. Others</li></ul></li><li>D. <i>Endocrinopathies:</i><ul style="list-style-type: none"><li>1. Acromegaly</li><li>2. Cushing's syndrome</li><li>3. Glucagonoma</li><li>4. Pheochromocytoma</li><li>5. Hyperthyroidism</li></ul></li></ul>

6. Somatostatinoma
7. Aldosteronoma
8. Others

*E. Drug- or chemical-induced:*

1. Vacor
2. Pentamidine
3. Nicotinic acid
4. Glucocorticoids
5. Thyroid hormone
6. Diazoxide

**Continued**

7. Thiazides
8. Dilantin
9.  $\alpha$ -Interferon
10. Others

*F. Infections:*

1. Congenital rubella
2. Cytomegalovirus
3. Others

*G. Uncommon forms of immune-mediated diabetes:*

1. "Stiff-man" syndrome
2. Anti-insulin receptor antibodies
3. Others

*H. Other genetic syndromes sometimes associated with diabetes:*

1. Down's syndrome
2. Klinefelter's syndrome
3. Turner's syndrome
4. Wolfram's syndrome
5. Friedreich's ataxia
6. Huntington's chorea
7. Laurence-Moon-Biedl syndrome
8. Myotonic dystrophy
9. Porphyria
10. Prader-Willi syndrome
11. Others

**IV. Gestational diabetes mellitus (GDM)**

(ADA, 2007).